Creative Biolabs Expands Functionalized Lipid Delivery Systems

Creative Biolabs has expanded its functionalized lipid-based delivery system development capabilities to help scientists overcome persistent challenges in therapeutic delivery. As researchers work with increasingly sophisticated small molecules, proteins, peptides, and nucleic acids, conventional liposomes often fall short in maintaining stability, reaching intended cells, overcoming biological barriers, and releasing cargo under appropriate physiological conditions. The company now supports customized targeted liposome development, encompassing targeting ligand selection, liposome formulation, surface modification, characterization, and optimization. This service allows researchers to conjugate antibodies, antibody fragments, peptides, proteins, carbohydrates, vitamins, and other ligands to liposomal surfaces, enabling molecular recognition and more selective delivery. For example, in tumor-targeting studies, a receptor-specific antibody fragment or peptide can be attached to the liposome surface and compared with an untargeted formulation to assess whether active targeting provides meaningful advantages.

Beyond targeting, Creative Biolabs supports the development of stimuli-responsive liposomes, including ROS-responsive liposomes and hypoxia-responsive liposomes. These systems are designed to remain stable until they encounter specific microenvironmental conditions, such as elevated reactive oxygen species or low-oxygen environments found in many solid tumors, and then release their payload. The company advises researchers to identify the primary delivery bottleneck first, match functionality to biological context, optimize formulation and function together, and test responsiveness against appropriate controls. By providing integrated support from design to validation, Creative Biolabs enables scientists to evaluate how lipid composition, surface engineering, payload characteristics, and biological conditions collectively influence delivery performance, ultimately helping to bridge the gap between promising bioactive molecules and effective experimental delivery.